The antibody attached to the virus in a way that stopped every variant seen so far
As new coronavirus variants threatened to outpace existing treatments in the spring of 2021, researchers at Baylor University Medical Center began testing a monoclonal antibody that had done something no previous compound had managed: neutralize every known variant of concern in the laboratory. Developed by Eli Lilly and AbCellera Biologics, LY-CoV1404 targeted a conserved region of the virus's spike protein — a part that had not mutated since the pandemic began — offering a potential foothold of stability in a rapidly shifting biological landscape. If the trials confirm what early science suggests, the drug could extend meaningful treatment to the unvaccinated and immunocompromised, and do so through a simple injection rather than a lengthy infusion, quietly expanding the geography of care.
- New coronavirus variants — including strains from the UK, South Africa, Brazil, India, and within the United States — were spreading faster than existing antibody treatments could reliably counter them.
- LY-CoV1404 neutralized all known variants in preliminary tests by binding to a part of the spike protein that has remained unchanged throughout the pandemic, a rare and significant finding.
- The possibility of delivering the drug as an intramuscular injection rather than an IV infusion could move treatment out of specialized clinics and into doctors' offices or homes, reaching patients who currently have no authorized therapy.
- Baylor's trial enrolled recently diagnosed, non-hospitalized adults, with a second phase set to include older and high-risk patients — the very populations most vulnerable if variants continue to evade immunity.
- Despite monoclonal antibodies reducing hospitalizations by roughly 70 percent when given early, they remain widely underused, and this trial represents an urgent attempt to close that gap before the variant landscape shifts again.
In the spring of 2021, as coronavirus variants spread across the United States and threatened to outpace existing treatments, Baylor University Medical Center began enrolling patients in a clinical trial for a monoclonal antibody with an unusual distinction: it had neutralized every known variant of concern in preliminary laboratory testing.
The drug, LY-CoV1404, was developed by Eli Lilly in partnership with AbCellera Biologics, a Vancouver-based company that screens blood from recovered COVID-19 patients to find naturally occurring antibodies. What made this compound different was where it attached to the virus — a region of the spike protein that had remained unchanged since the pandemic began, even as mutations elsewhere rendered older antibodies ineffective. It showed activity against variants from the UK, South Africa, Brazil, California, New York, and the double mutant strain circulating in India.
Beyond its broad efficacy, the drug carried a practical advantage. Because it appeared potent at lower doses, it might be given as a quick intramuscular injection rather than an intravenous infusion requiring hours in a specialized clinic. That shift could fundamentally expand access — moving treatment into ordinary doctors' offices or even patients' homes.
The Baylor trial initially enrolled adults ages 18 to 64 diagnosed with COVID-19 within the previous three days and not yet hospitalized. A second phase, expected to open within a week, would include those 65 and older or at high risk for severe disease, comparing LY-CoV1404 alone against a three-antibody combination that included it.
Dr. Robert Gottlieb, who oversaw the trials at Baylor, described the work as an effort to reach patients who currently had no authorized therapy. Monoclonal antibodies had already proven their value — reducing hospitalizations by roughly 70 percent when given early — yet remained underused. With the UK variant now dominant across the country and the Brazilian P.1 strain detected in the Dallas-Fort Worth area just days before the trial launched, the urgency was unmistakable. For those not yet vaccinated or whose immune systems limited vaccine effectiveness, this trial represented one of the clearest paths forward.
In the spring of 2021, as new coronavirus variants spread across the country and threatened to outpace existing treatments, researchers at Baylor University Medical Center began enrolling patients in a clinical trial for a monoclonal antibody that had shown an unusual promise: it worked against every known variant of concern.
The drug, called LY-CoV1404, was developed by Eli Lilly in partnership with AbCellera Biologics, a Vancouver-based company that hunts for antibodies to treat disease. In preliminary laboratory testing, the compound neutralized variants first identified in the United Kingdom, South Africa, Brazil, California, and New York. It also appeared effective against the double mutant strain circulating in India. The key to its broad effectiveness lay in where it attached to the virus. Most variants carried mutations on their spike proteins—the structures that allow the coronavirus to enter human cells—that rendered older antibodies useless. But this new antibody latched onto a part of the spike protein that had remained unchanged since the pandemic began.
AbCellera's CEO, Carl Hansen, described the mechanism with precision: the antibody attached to the virus in a way that stopped every variant the world had seen so far. The company had begun screening blood samples from recovered COVID-19 patients in January, specifically hunting for a compound that could neutralize emerging variants. What they found was a naturally occurring antibody, which they then synthesized into the drug now entering trials.
The potential advantage extended beyond efficacy. Because LY-CoV1404 appeared potent enough to work at lower doses, it might be administered as an intramuscular injection—a few seconds of needle work—rather than as an intravenous infusion that required patients to sit in specialized clinics for extended periods. This shift could fundamentally change who could access the treatment and where. Instead of traveling to infusion centers equipped to safely handle COVID-positive patients, people might receive antibodies at their doctor's office or even at home.
The trial at Baylor was designed to test the drug in healthy adults who had been diagnosed with COVID-19 within the previous three days and were not yet hospitalized. The initial phase enrolled people ages 18 to 64. A second phase, expected to open within a week, would include those 65 and older or at high risk for severe disease—populations already eligible for existing monoclonal antibody treatments under emergency authorization. That phase would compare the new single antibody against a combination of three antibodies that included LY-CoV1404.
Dr. Robert Gottlieb, who oversaw COVID-19 clinical trials at Baylor, framed the work as an opportunity for patients without other options. "This group of patients right now doesn't have access to a therapy, and we're looking to see if we can help them," he said. Monoclonal antibodies had proven their worth: when administered within days of symptom onset, they reduced hospitalizations by roughly 70 percent. Yet they remained underused, even though they were the only treatment authorized for non-hospitalized patients.
The timing of the trial reflected the urgency of the moment. The United Kingdom variant had become the dominant source of new infections across the United States. All major variants of concern had been detected in Texas, including the Brazilian P.1 strain, which was identified in the Dallas-Fort Worth area just days before the trial launched. These variants spread more quickly than the original coronavirus and showed signs of evading the human immune system, though vaccines still appeared effective against them. For people not yet vaccinated or with compromised immune systems that reduced vaccine effectiveness, monoclonal antibodies remained a critical tool.
Gottlieb saw the trial as emblematic of a shift in the pandemic's trajectory. "There is now an empowering message that if you have risk factors, we have evidence-based, proven therapies that are game-changing," he said. For those without risk factors, participation in trials like this one offered a chance to contribute to medical knowledge while potentially benefiting their own health. The landscape had changed dramatically in a year.
Notable Quotes
This group of patients right now doesn't have access to a therapy, and we're looking to see if we can help them.— Dr. Robert Gottlieb, Baylor University Medical Center
We suspect that this antibody will be available to be used in the future, regardless of the variants that arise.— Bo Barnhart, AbCellera's scientific director
The Hearth Conversation Another angle on the story
Why does it matter that this antibody works against all the variants they tested, rather than just some of them?
Because variants were making the old antibodies obsolete. The virus kept changing the lock, and the old keys stopped fitting. If you have a treatment that works against every variant you've seen, you're not constantly chasing a moving target. You have something stable to build on.
The source mentions this could be given as a shot instead of an IV. How much does that actually change things for patients?
It changes everything about access. Right now, you have to go to a specialized clinic, sit for an infusion, wait. If it's a shot, you can get it at your doctor's office or at home. That's the difference between a treatment that reaches thousands and one that reaches millions.
The trial is only enrolling people ages 18 to 64 in the first phase. Why exclude older people initially?
The older population already has access to existing monoclonal antibodies under emergency authorization. The trial is looking at people who have no approved options right now. The second phase will compare this new drug to the existing combination treatments in the higher-risk groups.
What's the significance of the antibody attaching to a part of the spike protein that hasn't changed?
It's the difference between chasing variants forever and having something that might work regardless of what comes next. If that part of the protein is truly conserved—if the virus can't change it without losing function—then you've found something durable.
The article mentions vaccines are still effective against variants. So why do we need this antibody?
Vaccines are excellent, but they take time to work and they're less effective in people with compromised immune systems. This antibody works immediately, within days of infection. For the unvaccinated and the immunocompromised, it's the only tool that works fast enough.